QUALIGEN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.305 USD | +6.09% |
|
+4.10% | -44.55% |
Presenter SpeechUnknown Attendee (Attendees)So doctor, thank you very much for taking the time...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Companyâs business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genesâ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.55% | 1.81M | |
| +67.53% | 62.86B | |
| -0.77% | 41.38B | |
| +45.66% | 40.38B | |
| -10.72% | 27.64B | |
| +13.30% | 26.46B | |
| -22.79% | 18.9B | |
| +4.70% | 12.67B | |
| +24.10% | 12.27B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- QLGN Stock
- News Qualigen Therapeutics, Inc.
- Transcript : Ritter Pharmaceuticals, Inc. - Special Call
